Nature Communications (Jun 2020)
Oncolytic virus-derived type I interferon restricts CAR T cell therapy
- Laura Evgin,
- Amanda L. Huff,
- Phonphimon Wongthida,
- Jill Thompson,
- Tim Kottke,
- Jason Tonne,
- Matthew Schuelke,
- Katayoun Ayasoufi,
- Christopher B. Driscoll,
- Kevin G. Shim,
- Pierce Reynolds,
- Dileep D. Monie,
- Aaron J. Johnson,
- Matt Coffey,
- Sarah L. Young,
- Gary Archer,
- John Sampson,
- Jose Pulido,
- Luis Sanchez Perez,
- Richard Vile
Affiliations
- Laura Evgin
- Department of Molecular Medicine, Mayo Clinic
- Amanda L. Huff
- Department of Molecular Medicine, Mayo Clinic
- Phonphimon Wongthida
- Department of Molecular Medicine, Mayo Clinic
- Jill Thompson
- Department of Molecular Medicine, Mayo Clinic
- Tim Kottke
- Department of Molecular Medicine, Mayo Clinic
- Jason Tonne
- Department of Molecular Medicine, Mayo Clinic
- Matthew Schuelke
- Department of Immunology, Mayo Clinic
- Katayoun Ayasoufi
- Department of Immunology, Mayo Clinic
- Christopher B. Driscoll
- Department of Molecular Medicine, Mayo Clinic
- Kevin G. Shim
- Department of Immunology, Mayo Clinic
- Pierce Reynolds
- Department of Molecular Medicine, Mayo Clinic
- Dileep D. Monie
- Department of Molecular Medicine, Mayo Clinic
- Aaron J. Johnson
- Department of Immunology, Mayo Clinic
- Matt Coffey
- Oncolytics Biotech Incorporated
- Sarah L. Young
- Department of Pathology, Dunedin School of Medicine, University of Otago
- Gary Archer
- Department of Neurosurgery, Duke University
- John Sampson
- Department of Neurosurgery, Duke University
- Jose Pulido
- Department of Ophthalmology, Mayo Clinic
- Luis Sanchez Perez
- Department of Neurosurgery, Duke University
- Richard Vile
- Department of Molecular Medicine, Mayo Clinic
- DOI
- https://doi.org/10.1038/s41467-020-17011-z
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Oncolytic viruses promote an inflammatory response and elicit anti-tumor immunity. Here the authors show, unexpectedly, that the oncolytic virus, VSVIFNβ, induces type I interferon responses that, when combined with chimeric antigen receptor (CAR) T therapy, lead to the attrition of both CAR T and conventional T cells, thus dampening their anti-tumor activity.
